Central Pacific Bank Trust Division Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Central Pacific Bank Trust Division bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,290 shares of the company’s stock, valued at approximately $513,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rise Advisors LLC bought a new stake in Medpace during the first quarter worth about $27,000. Mather Group LLC. bought a new stake in Medpace during the first quarter worth about $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace during the first quarter worth about $31,000. Contravisory Investment Management Inc. bought a new stake in Medpace during the fourth quarter worth about $26,000. Finally, RiverPark Advisors LLC bought a new stake in Medpace during the fourth quarter worth about $26,000. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MEDP shares. Robert W. Baird boosted their price target on Medpace from $456.00 to $469.00 and gave the stock an “outperform” rating in a research report on Monday. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Friday, June 7th. Mizuho began coverage on Medpace in a research report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. TD Cowen began coverage on Medpace in a research report on Wednesday, May 29th. They issued a “buy” rating and a $452.00 target price on the stock. Finally, Guggenheim upped their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Moderate Buy” and an average price target of $445.29.

Medpace Stock Up 1.9 %

Shares of Medpace stock traded up $7.82 on Wednesday, hitting $418.77. The stock had a trading volume of 18,745 shares, compared to its average volume of 226,874. Medpace Holdings, Inc. has a twelve month low of $227.21 and a twelve month high of $437.39. The business’s 50 day moving average is $398.76 and its two-hundred day moving average is $373.02. The stock has a market cap of $12.97 billion, a price-to-earnings ratio of 41.89, a price-to-earnings-growth ratio of 2.01 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The company’s revenue was up 17.7% on a year-over-year basis. During the same quarter last year, the company earned $2.27 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the transaction, the chief executive officer now directly owns 791,541 shares in the company, valued at approximately $317,162,563.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 3,987 shares of the company’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares of the company’s stock, valued at $260,983,922.22. The disclosure for this sale can be found here. Insiders sold 29,621 shares of company stock valued at $11,816,852 over the last quarter. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.